Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Published 2010 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 11, Issue 12, Pages 1149-1159

Publisher

Elsevier BV

Online

2010-11-20

DOI

10.1016/s1470-2045(10)70261-8

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Publish scientific posters with Peeref